References
- Guidelines Committee The 2003 European Society of Hypertension - European Society of Cardiology Guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53.
- Culleton BF, Larson MG, Wilson PW, Evans JC, Parfrey PS, Levy D. Cardiovascular disease and mortality in a commu-nity-based cohort with mild renal insufficiency. Kidney Int 1999; 56: 2214–19.
- Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–70.
- Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hyper-tension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218–25.
- Ruilope LM, Rodicio JL. Clinical relevance of proteinuria and microalbuminuria. Curr Opin Nephrol Hypertens 1993; 2: 962–7.
- Parving HH. Initiation and progression of diabetic nephro-pathy. N Engl J Med 1996; 335: 1682–3.
- Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980; 93: 817–21.
- Adler Al, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR, UKPDS GROUP. Development and progres-sion of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225–32.
- Redon J, Williams B. Microalbuminuria in essential hyper- tension: redefining the threshold. J Hypertens 2002; 20: 353–5.
- Hillege HL, Fidler V, Diercks GFH, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al, for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777–82.
- Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjwr H. Microalbuminuria and all-cause mortality in 2089 appar-ently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis 2003; 42: 466–73.
- Zanchetti A, Hansson L, Dahlof B, Elmfeldt D, Kjeldsen S, Kolloch R, et al. Effects of individual risk factors on the incidence of cardiovascular events in the treated hyper-tensive patients of the Hypertension Optimal Treatment Study. HOT Study Group. J Hypertens 2001; 19: 1149–59.
- Leoo T, Odar-Cederlöf I. Testing for microalbuminuria and albuminuria in diabetes is as important as checking blood pressure. Blood Press 2004; 6: 326–329.
- Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, et al. Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hyper-trophy: the LIFE study. Blood Press 2004; 6: 376–384.
- Wachtell K, Olsen MH, Dahlöf B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hyperter-ophy: the LIFE study. J Hypertens 2002; 20: 405–12.
- Sorensen K, Kristensen KS, Bang LE, Svendsen TL, Wiinberg N, Buttenschön L, et al. Increased systolic ambulatory blood pressure and microalbuminuria in treated and non-treated hypertensive smokers. Blood Press 2004; 6: 362–368.